TSR-033 

TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

TSR-033 (0.01-1000 nmol/L, 48 h) increases IL2 production by primary human CD4 T cells and dendritic cells and enhanced T cell effector function^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TSR-033(i.p.,10 mg/kg, twice weekly, 40 days) has a moderate inhibitory effect on tumor growth with a TGI of 23% at termination by treatment with alone, while the combination with TSR-042 had a cumulative effect, impeding tumor growth to a greater extent, with a TGI of 45% at termination in A549 HuNOG-EXL NSCLC mice tumor model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2225940-96-3

Liquid

Colorless to light yellow

[3H]S[R033]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Srimoyee Ghosh, et al. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Mol Cancer Ther. 2019 Mar;18(3):632-641.  [Content Brief]